Annual report
9265.TEDINET S100WKIB
Period2024-06-01 → 2025-05-31
Filed2025-08-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥64.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales |
| Revenue | ¥61.6bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales |
| Revenue | ¥58.2bn | 2022-06-01 → 2023-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥55.1bn | 2021-06-01 → 2022-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥70.1bn | 2020-06-01 → 2021-05-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥838m | 2024-06-01 → 2025-05-31 | Cons. | Operating income |
| Operating income | ¥967m | 2023-06-01 → 2024-05-31 | Cons. | Operating income |
| Ordinary income | ¥909m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-06-01 → 2023-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2021-06-01 → 2022-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2020-06-01 → 2021-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥943m | 2024-06-01 → 2025-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥871m | 2023-06-01 → 2024-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥616m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥580m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥219m | 2022-06-01 → 2023-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥696m | 2021-06-01 → 2022-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥678m | 2020-06-01 → 2021-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥614m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss |
| Net income | ¥577m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss |
| Total assets | ¥27.5bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥26.6bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥24.6bn | at 2023-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.1bn | at 2022-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.3bn | at 2021-05-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥18.6bn | at 2025-05-31 | Cons. | Liabilities |
| Total liabilities | ¥18.0bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥9.0bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2023-05-31v | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-05-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥7.6bn | at 2021-05-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.7bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.3bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.7bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.3bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2023-05-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-05-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.7bn | at 2021-05-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥617m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥878m | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.2bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥581m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥911m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥19m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥107m | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥27m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥134m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥240m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥335m | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥209m | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥229m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥137m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥249.79 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥227.96 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.83 | 2022-06-01 → 2023-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥272.67 | 2021-06-01 → 2022-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥265.77 | 2020-06-01 → 2021-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,640.22 | at 2025-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,429.08 | at 2024-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,097.34 | at 2023-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,126.18 | at 2022-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,969.03 | at 2021-05-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 32.6% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2023-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2022-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.2% | at 2021-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.0% | 2024-06-01 → 2025-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2023-06-01 → 2024-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2022-06-01 → 2023-05-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2021-06-01 → 2022-05-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.3% | 2020-06-01 → 2021-05-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 613 | at 2025-05-31 | Cons. | Number of employees |
| Employees | 606 | at 2024-05-31 | Cons. | Number of employees |
| Employees | 570 | at 2023-05-31v | Cons. | Number of employees |
| Employees | 574 | at 2022-05-31v | Cons. | Number of employees |
| Employees | 553 | at 2021-05-31d | Cons. | Number of employees |
| Revenue | ¥1.4bn | 2024-06-01 → 2025-05-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.4bn | 2023-06-01 → 2024-05-31 | Standalone | Operating revenue1 |
| Revenue | ¥498m | 2022-06-01 → 2023-05-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥792m | 2021-06-01 → 2022-05-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥854m | 2020-06-01 → 2021-05-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥729m | 2024-06-01 → 2025-05-31 | Standalone | Operating income |
| Operating income | ¥763m | 2023-06-01 → 2024-05-31 | Standalone | Operating income |
| Ordinary income | ¥728m | 2024-06-01 → 2025-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥764m | 2023-06-01 → 2024-05-31 | Standalone | Ordinary income |
| Ordinary income | −¥16m | 2022-06-01 → 2023-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥227m | 2021-06-01 → 2022-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥347m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥728m | 2024-06-01 → 2025-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥764m | 2023-06-01 → 2024-05-31 | Standalone | Income before income taxes |
| Net income | ¥718m | 2024-06-01 → 2025-05-31 | Standalone | Profit loss |
| Net income | ¥767m | 2023-06-01 → 2024-05-31 | Standalone | Profit loss |
| Net income | −¥13m | 2022-06-01 → 2023-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥228m | 2021-06-01 → 2022-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥348m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.5bn | at 2025-05-31 | Standalone | Assets |
| Total assets | ¥8.0bn | at 2024-05-31 | Standalone | Assets |
| Total assets | ¥6.3bn | at 2023-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.5bn | at 2022-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.4bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.8bn | at 2025-05-31 | Standalone | Liabilities |
| Total liabilities | ¥1.8bn | at 2024-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥6.8bn | at 2025-05-31 | Standalone | Net assets |
| Net assets / equity | ¥6.3bn | at 2024-05-31 | Standalone | Net assets |
| Net assets / equity | ¥5.8bn | at 2023-05-31v | Standalone | Net assets |
| Net assets / equity | ¥6.0bn | at 2022-05-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥6.0bn | at 2021-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥732m | at 2025-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥312m | at 2024-05-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥291.15 | 2024-06-01 → 2025-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥301.31 | 2023-06-01 → 2024-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.29 | 2022-06-01 → 2023-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.32 | 2021-06-01 → 2022-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥136.46 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥75 | 2024-06-01 → 2025-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2023-06-01 → 2024-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2022-06-01 → 2023-05-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥82 | 2021-06-01 → 2022-05-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥90 | 2020-06-01 → 2021-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,741.18 | at 2025-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,521.27 | at 2024-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,272.88 | at 2023-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,360.07 | at 2022-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,360.75 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 79.2% | at 2025-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2024-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.2% | at 2023-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.4% | at 2022-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.8% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 11.0% | 2024-06-01 → 2025-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.7% | 2023-06-01 → 2024-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -0.2% | 2022-06-01 → 2023-05-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2021-06-01 → 2022-05-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,553,000 | at 2025-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2024-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2023-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2022-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 30 | at 2025-05-31 | Standalone | Number of employees |
| Employees | 29 | at 2024-05-31 | Standalone | Number of employees |
| Employees | 30 | at 2023-05-31v | Standalone | Number of employees |
| Employees | 27 | at 2022-05-31v | Standalone | Number of employees |
| Employees | 24 | at 2021-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2024-06-01 → 2025-05-31 | ¥37m |
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2025-05-31 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2025-05-31 | −¥1.1bn |
| Medical Equipment Manufacturing And Salesreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥6m |
| Medical Equipment Manufacturing And Salesreportable segment | employees | at 2025-05-31 | 7 pure |
| Medical Equipment Manufacturing And Salesreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥219m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥219m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2024-06-01 → 2025-05-31 | −¥220m |
| Medical Equipment Salesreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥122m |
| Medical Equipment Salesreportable segment | employees | at 2025-05-31 | 561 pure |
| Medical Equipment Salesreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥64.2bn |
| Medical Equipment Salesreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥64.2bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| Medical Equipment Salesreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥2.2bn |
| Medical Mallreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥14m |
| Medical Mallreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥72m |
| Medical Mallreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥72m |
| Medical Mallreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥5m |
| —segment total | depreciation | 2024-06-01 → 2025-05-31 | ¥143m |
| —segment total | revenue | 2024-06-01 → 2025-05-31 | ¥64.5bn |
| —segment total | revenue external | 2024-06-01 → 2025-05-31 | ¥64.5bn |
| —segment total | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| —segment total | segment profit | 2024-06-01 → 2025-05-31 | ¥2.0bn |
| Reconciling Itemsreconciling | depreciation | 2023-06-01 → 2024-05-31 | ¥27m |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2024-05-31 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2024-05-31 | −¥1m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2024-05-31 | −¥1.2bn |
| Medical Equipment Manufacturing And Salesreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥2m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥267m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥267m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥0 |
| Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2023-06-01 → 2024-05-31 | −¥1m |
| Medical Equipment Salesreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥138m |
| Medical Equipment Salesreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥61.2bn |
| Medical Equipment Salesreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥61.2bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥0 |
| Medical Equipment Salesreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥2.2bn |
| Medical Mallreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥16m |
| Medical Mallreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥68m |
| Medical Mallreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥68m |
| Medical Mallreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥0 |
| —segment total | depreciation | 2023-06-01 → 2024-05-31 | ¥157m |
| —segment total | revenue | 2023-06-01 → 2024-05-31 | ¥61.6bn |
| —segment total | revenue external | 2023-06-01 → 2024-05-31 | ¥61.6bn |
| —segment total | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥1m |
| —segment total | segment profit | 2023-06-01 → 2024-05-31 | ¥2.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,479
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash dividends paid fin cf | CurrentYearDuration | -174000000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -335000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -240000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | -524000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 397000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 5825000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 5300000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 5300000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 5698000000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 9 | |
| Notes receivable trade | Prior1YearInstant | 107000000 | JPY |
| Notes receivable trade | CurrentYearInstant | 101000000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 11152000000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 11773000000 | JPY |
| Electronically recorded monetary claims operating | Prior1YearInstant | 350000000 | JPY |
| Electronically recorded monetary claims operating | CurrentYearInstant | 340000000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 5000000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 166000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentSalesReportableSegmentsMember | 61219000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentManufacturingAndSalesReportableSegmentMember | 267000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalMallReportableSegmentsMember | 68000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 61555000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 61555000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentSalesReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentManufacturingAndSalesReportableSegmentMember | 0 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalMallReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -1000000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentSalesReportableSegmentsMember | 61220000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentManufacturingAndSalesReportableSegmentMember | 267000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalMallReportableSegmentsMember | 68000000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 61556000000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | -1000000 | JPY |
| Net sales | Prior1YearDuration | 61555000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentSalesReportableSegmentsMember | 2171000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentManufacturingAndSalesReportableSegmentMember | -1000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalMallReportableSegmentsMember | 0 | JPY |
| Operating income | Prior1YearDuration_ReportableSegmentsMember | 2170000000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | -1202000000 | JPY |
| Operating income | Prior1YearDuration | 967000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentSalesReportableSegmentsMember | 138000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentManufacturingAndSalesReportableSegmentMember | 2000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalMallReportableSegmentsMember | 16000000 | JPY |
| Depreciation segment information | Prior1YearDuration_ReportableSegmentsMember | 157000000 | JPY |
| Depreciation segment information | Prior1YearDuration_ReconcilingItemsMember | 27000000 | JPY |
| Depreciation segment information | Prior1YearDuration | 185000000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentSalesReportableSegmentsMember | 200000000 | JPY |
| Impairment loss el | Prior1YearDuration_jpcrp030000-asr_E33393-000MedicalEquipmentManufacturingAndSalesReportableSegmentMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |